Fig. 3

CAFs viability after calcitriol treatment. A data presented for CAFs from all patients. B1 data presented for CAFs derived from metastatic (n = 13) or nonmetastatic tumors (n = 23). B2 data presented for CAFs derived from tumors from pre- (n = 15) or postmenopausal patients (n = 21). B3 data presented for CAFs derived from tumors of patients with deficient (n = 24) or normal plasma 25(OH)D₃ levels (n = 12). CAFs were stimulated with different calcitriol concentrations (1 nM, 10 nM, 100 nM, or 1000 nM) for 72 h. Patients were classified into groups according to plasma 25(OH)D₃ levels (VD3, < 30 ng/mL—deficient, > 30 ng/mL—normal), plasma FSH levels (< 25.8 mIU/mL—premenopausal, > 25.8 mIU/mL—postmenopausal) and regional or distant metastasis presence (if any—metastatic, otherwise nonmetastatic). Viability was calculated as a percentage of untreated cells. Data are presented as the mean ± SD. Statistical analysis was carried out using Student’s t-test or the Mann‒Whitney U test for single comparisons and one-way ANOVA for multiple comparisons. *p ≤ 0.05 compared to untreated cells. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001